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Toll-like receptors (TLRs) play central roles in the innate immune response by recognizing conserved struc-
tural patterns in diverse microbial molecules. Here, we discuss ligand binding and activation mechanisms of
the TLR family. Hydrophobic ligands of TLR1, TLR2, and TLR4 interact with internal protein pockets. In
contrast, dsRNA, a hydrophilic ligand, interacts with the solvent-exposed surface of TLR3. Binding of ago-
nistic ligands, lipopeptides or dsRNA, induces dimerization of the ectodomains of the various TLRs, forming
dimers that are strikingly similar in shape. In these ‘‘m’’-shaped complexes, the C termini of the extracellular
domains of the TLRs converge in the middle. This observation suggests the hypothesis that dimerization of
the extracellular domains forces the intracellular TIR domains to dimerize, and this initiates signaling by
recruiting intracellular adaptor proteins.Introduction
Ten human Toll-like receptors (TLRs) have been discovered
since TLR4 was first identified as the ortholog of Drosophila
Toll (Gay and Keith, 1991; Medzhitov et al., 1997). Toll and the
TLRs are critical for the innate immune response in Drosophila
and mammals, respectively. TLRs are type I transmembrane
glycoproteins composed of extracellular, transmembrane and
intracellular signaling domains (Gay and Gangloff, 2007). The ex-
tracellular domains have repeated leucine-rich repeat (LRR)
modules and are responsible for binding so-called ‘‘pathogen-
associated molecular patterns’’ (PAMPs) (Janeway, 1989;
Medzhitov, 2001). For example, lipoproteins or lipopeptides
are recognized by TLR2 in complex with TLR1 or TLR6, viral dou-
ble-stranded RNA are recognized by TLR3, lipopolysaccharide
are recognized by TLR4, flagellin are recognized by TLR5, single-
stranded RNA are recognized by TLR7 or TLR8, and microbial
DNAs are recognized by TLR9 (Uematsu and Akira, 2008).
Ligand-induced dimerization of TLRs is believed to trigger re-
cruitment of adaptor proteins to the intracellular TIR (Toll/inter-
leukin-1 receptor) domains to initiate signaling (O’Neill and
Bowie, 2007). Intracellular TIR domains are composed of 150
amino acid residues. The signaling cascades via the TIR do-
mains are mediated by specific adaptor molecules including
MyD88, MAL (also known as TIRAP), TRIF, and TRAM (O’Neill
and Bowie, 2007). These adaptor proteins also contain TIR do-
mains and TIR-TIR interactions between receptor-receptor, re-
ceptor-adaptor, and adaptor-adaptor are critical for activating
signaling (Pa˚lsson-McDermott and O’Neill, 2007).
Structural studies of TLR-ligand complexes have been an at-
tractive area of research given that structural information is crit-
ical for understanding innate immunity as well as designing novel
drugs. In 2005, Choe et al. (2005), and later Bell et al. (2005), first
reported crystal structures of human TLR3 in atomic detail.
These structures did not contain bound ligands. Subsequently,
three structures of TLR-ligand complexes, TLR1-TLR2-lipopep-
tide, TLR4-MD-2-Eritoran, and TLR3-double-stranded RNA
(dsRNA), have been determined by others and by us, and they
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nize a remarkably large variety of ligands, and how the agonists
induce dimerization of the receptors (Jin et al., 2007; Kim et al.,
2007b; Liu et al., 2008). In this review, we summarize the
reported structures of the TLR complexes and discuss their
implications for our understanding of TLR activation.
Structure of the Extracellular Domains of the TLR Family
The extracellular domains of TLR family proteins contain 16–28
LRRs (Matsushima et al., 2007). The LRR family comprises ap-
proximately 6000 proteins in the Pfam database (http://pfam.
sanger.ac.uk). They are involved in a wide variety of physiologi-
cal functions including immune responses, signal transduction,
cell-cycle regulation, enzyme regulation, etc. (Dolan et al.,
2007; Matsushima et al., 2005). All known LRR family proteins
contain multiple LRR modules. The shorter LRR proteins have
two to three LRR modules but the longer ones can have more
than 40. The individual LRR module is 20–30 amino acids long
and is composed of a conserved ‘‘LxxLxLxxN’’ motif and a vari-
able part (Kajava, 1998; Kobe and Kajava, 2001). Nearly 50 crys-
tal structures of the LRR family have been reported in the Protein
Data Bank database. All these structures have a common horse-
shoe-like shape (Gay and Gangloff, 2007). The hydrophobic
core, formed by the conserved leucines and hydrophobic resi-
dues in the variable regions, extends throughout the entire pro-
tein. The LRRNT and LRRCT modules in the N and C termini
do not have LRRmotives but frequently contain clustered cyste-
ines forming disulfide bridges (Kajava, 1998; Kobe and Kajava,
2001; Matsushima et al., 2007). These modules stabilize the pro-
tein by protecting its hydrophobic core from being exposed to
solvent. The unique horseshoe-like shape is due to conserved
sequence patterns in the LRR modules. The ‘‘LxxLxLxxN’’ mo-
tives are located in the inner concave surfaces of the horse-
shoe-like structure formed from parallel b strands. The variable
parts of the modules form the convex surface generated by
helices, b turns, and/or loops.
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cluding TLRs have proven to be extremely difficult. To overcome
these problems, we developed a method termed the ‘‘hybrid
LRR technique’’ (Jin et al., 2007; Kim et al., 2007b). This tech-
nique was applied to the TLR family and enabled us to determine
the crystal structures of three TLR proteins, TLR1, TLR2, and
TLR4, and their complexes with ligands. Hagfish variable lym-
phocyte receptors (VLRs) were chosen as the fusion partners,
and the TLR and the VLR fragments were fused at their con-
served ‘‘LxxLxLxxN’’ motifs so that local structural incompatibil-
ity could be minimized (Kim et al., 2007a). Analysis of seven
TLR-VLR hybrids demonstrated that the fusion strategy did not
disturb the structure or function of any of the proteins (Jin et al.,
2007; Kim et al., 2007b).
On the basis of their sequences and structural patterns,
LRR family proteins can be classified into seven subfamilies,
‘‘typical,’’ ‘‘RI-like (ribonuclease inhibitor-like),’’ ‘‘CC (cysteine
containing),’’ ‘‘PS (plant specific),’’ ‘‘SDS22-like (SDS22+ protein-
like),’’ ‘‘bacterial,’’ and ‘‘TpLRR (Treponema pallidum LRR)’’
(Kajava, 1998; Kobe and Kajava, 2001; Matsushima et al.,
2007). TLRs are ‘‘typical’’ subfamily proteins. These have
LRR modules of 24 amino acids with the conserved motif
‘‘xLxxLxxLxLxxNxLxxLPxxxFx.’’ In addition to the b sheet in
the concave region common to all LRR family, the typical sub-
family member contains parallel 310 helices (a form of secondary
structure) in the convex region of the horseshoe-like structure.
The LRRmodules of TLR1, TLR2, and TLR4 deviate substantially
in conformation from those of other ‘‘typical’’ subfamily proteins
(Jin et al., 2007; Kim et al., 2007b). The three TLRs have two
sharp structural transitions in the b sheet, and therefore their
LRR domains can be divided into three subdomains, N terminal,
central, and C terminal. The central domains have radii, twist and
tilt angles that deviate markedly from the standard values of the
‘‘typical’’ subfamily member. These atypical structures seem to
be caused by unusual LRRmodules concentrated in their central
domains. First, the central domains of TLR1, TLR2, and TLR4
lack asparagine ladders that stabilize the overall horseshoe-
like structure by forming a continuous hydrogen-bond network
with backbone oxygens of the neighboring b strands. The broken
asparagine ladders in the central domains may allow the unusual
structural distortions found in TLR1s, TLR2s, and TLR4s. Sec-
ond, the LRR modules of the central domains vary considerably
in numbers of residues, which range from 20 to 33 residues. The
LRR modules in the majority of the LRR proteins are of uniform
length (Kajava, 1998; Kobe and Kajava, 2001; Matsushima
et al., 2007). LRR subfamilies with shorter LRR modules have
loops in the convex area, and those containing longer LRRmod-
ules have bulkier a helices. Helices require more space than
loops and therefore subfamilies with a helices have smaller radii
compared to those with loops that generate enough space in the
convex region. Therefore, the large variation in the length of the
central domain should contribute to the structural anomalies
found in the TLRs. Third, the central domains of TLR1, TLR2,
and TLR4 have one or more a helices inserted into the convex
area. The insertion of the bulkier a helices in some of these
LRR modules should increase the curvature of the domains
and contribute to the unusually small and nonuniform radii of
the central domains. The structural alterations in TLR1, TLR2,
and TLR4 are associated with their biological functions becausethey play essential roles in binding ligands or coreceptors (see
Structure of TLRs and Their Ligand Complexes). The N- and
C-terminal domains agree well with consensus structure of the
typical subfamily: The length of LRR modules varies little around
a value of 24 amino acid residues, and the structurally important
asparagine ladder and phenylalanine spine are conserved.
In contrast to TLR1, TLR2, and TLR4, TLR3 has a flat horse-
shoe-like shape with uniform conformational angles comparable
to those of other LRR proteins of the ‘‘typical’’ subfamily (Bell
et al., 2005; Choe et al., 2005; Liu et al., 2008). The asparagine
ladders are intact throughout the TLR3molecule, and the lengths
of the LRR modules vary considerably less than those of TLR1,
TLR2, or TLR4. Although the structures of TLR5, TLR7, TLR8,
and TLR9 have not yet been reported, their LRRmodules appear
to have continuous asparagines ladders and relatively uniform
module lengths, suggesting that they belong to the single do-
main subfamily. In contrast, TLR6 and TLR10 have LRRmodules
with broken asparagine ladders and greater variation in module
length in the central part of the protein. They probably belong
to the three-domain architecture found in TLR1, TLR2, and TLR4.
Structures of the Intracellular TIR Domains of TLRs
and Signaling Adapters
The structures of the TIR domains of TLR1, TLR2, and TLR10
have been studied by X-ray crystallography (Nyman et al.,
2008; Xu et al., 2000). These domains have a common fold
containing a five-stranded b sheet surrounded by five a helices.
Mutational and modeling studies indicate that the BB loop
connecting the second b sheet and the second a-helix plays
an important role in TIR dimerization and/or adaptor recruitment.
Mutation Pro681His in the TLR2 BB loop abolished signal
transduction in response to stimulation by yeast and Gram-pos-
itive bacteria (Underhill et al., 1999). The Pro681His mutation did
not cause noticeable structural changes but disrupted the phys-
ical interaction between the TIR domains of TLR2 andMyD88 (Xu
et al., 2000). Modeling and docking analyses predict that electro-
static complementarity plays the main role in the interaction be-
tween TIR domains (Dunne et al., 2003; Gautam et al., 2006). In-
terestingly, in a recent crystal structure, the BB loop of the TIR
domain of TLR10 was shown to be involved in the homodimeric
interaction with a neighboring TIR domain in the crystal (Nyman
et al., 2008). However, it is not certain whether the homodimeric
structure seen in the crystal corresponds to a physiologically rel-
evant dimer of the TLR10 TIR domains because the TIR domain
of TLR10 exists as a monomer in solution.
Experimental structure determination of the TIR multimer is
severely hampered by the low affinity between isolated TIR do-
mains in solution (Xu et al., 2000). Therefore, several modeling
studies have been performed to predict the structures of TIR
multimers. Gautam et al. proposed that the DD loop of TLR2 con-
necting the fourth b sheet and the fourth a-helix is positioned in
close contact with the BB loop of TLR1 (Gautam et al., 2006). In
support of the modeling result, a Gly676Leu substitution in the
BB loop of the TLR1 TIR domain was shown to interfere with sig-
naling. Other groups have proposed models for the TIR domain
of TLR4 with the structure of the TIR domains of TLR2 as tem-
plate. For example, Dunne et al. suggests in their model that
MAL and MyD88 bind to different regions in TLR4, thereby form-
ing a heterotetrameric receptor-adaptor complex (Dunne et al.,
Immunity 29, August 15, 2008 ª2008 Elsevier Inc. 183
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model using the crystal structure of the TLR10 TIR domain as
template (Nu´n˜ez Miguel et al., 2007). They hypothesized that
the TIR dimers found in crystals of the TLR10 TIR domain mimic
physiological dimers and built a model of dimeric TLR4 TIR on
the basis of this idea. In their model, the BB loops of the two
TLR4 TIRs interact in a symmetric fashion. They also proposed
that MAL and TRAM TIRs interact at the dimeric interface
between the two TLR4 TIR domains.
Structure of TLRs and Their Ligand Complexes:
TLR1-TLR2-Ligand Interaction
Recently, three crystallographic structures of the extracellular
domains of TLRs and their ligand complexes have been reported
(Jin et al., 2007; Kim et al., 2007b; Liu et al., 2008). Two of them
were complexed with agonistic ligands and the remaining one
was complexed with a coreceptor and an antagonistic ligand.
They provide the first clues as to how these pattern-recognition
receptors recognize ‘‘patterns’’ in the ligands. They also suggest
an activation mechanism that may be common to all TLR family
receptors.
TLR2 in association with TLR1 or TLR6 is essential for recog-
nizing bacterial lipoproteins and lipopeptides. Lipoproteins are
found in more than 400 proteins from all kinds of bacteria
(Babu et al., 2006). They are anchored to the cellular membrane
via lipid chains attached to conserved N termini and induce
strong proinflammatory responses from macrophages (Cham-
baud et al., 1999). Most bacteria except mycoplasmas produce
lipoproteins with three lipid chains (Hantke and Braun, 1973;
Muhlradt et al., 1997; Shibata et al., 2000). Their invariant N-ter-
minal cysteines are covalently attached to a diacylglyceryl chain
via a thioether bond, and they are further modified by the third
acyl chain’s being connected by an amide linkage to the N-termi-
nal cysteine (Figure 1A). The lipopeptides produced by myco-
plasmas do not have the amide-linked acyl chain and therefore
contain only two acyl chains. Palmitoyl groups are by far the
most common lipids in the lipoproteins, and the composition of
the lipid chains closely resembles that of membrane phospho-
lipids (Belisle et al., 1994; Braun, 1975; Mizuno, 1979; Zlotnick
et al., 1988). Other than the lipidmodifications and the shared se-
quence patterns found in the N termini, bacterial lipoproteins do
not have any similarities of sequence or function. The acyl-
glyceryl cysteine appears to be the structure recognized by
TLRs because synthetic lipopeptides that havemost of their pro-
tein residues except the N-terminal cysteine removed still retain
full immune stimulatory activity (Berg et al., 1994; Bessler et al.,
1985; Seifert et al., 1990; Wiesmuller et al., 1992). Previous stud-
ies have shown that TLR2 is the main receptor recognizing lipo-
proteins and lipopeptides. Triacylated lipoproteins are recog-
nized by the TLR1-TLR2 complex (Shimizu et al., 2007;
Takeuchi et al., 2002), but diacylated lipopeptides, lacking the
amide-bound lipid chain, can activate both of the TLR1-TLR2
and TLR2-TLR6 complexes (Buwitt-Beckmann et al., 2005;
Takeuchi et al., 2001).
We recently determined the crystal structure of the extracellu-
lar domain of TLR2 in association with TLR1 and a synthetic tri-
acylated lipopeptide, Pam3CSK4 (Jin et al., 2007). Pam3CSK4 is
a synthetic derivative of triacylated lipoproteins that retains most
of immune stimulatory activity of full-length lipoproteins. Without
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eluted as monomers in gel-filtration chromatography. However,
after addition of the agonistic lipopeptide, the TLRs formed a sta-
ble heterodimer in solution as well as in the crystals. In the crystal
structure, the lipid chains of the ligand bridge the TLRs; two of
the three lipid chains are inserted into an internal pocket in
TLR2, and the remaining amide-bound lipid chain is inserted
into the narrower channel in TLR1 (Figure 1B). The ligand-binding
pockets of TLR1 and TLR2 are located at the boundary of the
central and C-terminal domain in the convex region. The flexible
loops at the domain boundaries are separated, forming crevices
that are connected to large internal pockets. The pockets of
TLR1 and TLR2 are bridged by the bound ligand and therefore
form a long continuous hydrophobic pocket. Structural flexibility
Figure 1. TLR1, TLR2, and Ligand Interaction
(A) Chemical structures of a diacylated lipopeptide, MALP-2 from M. fermen-
tans, and triacylated lipoproteins-natural Outer surface protein A (OspA) from
B. burgdorferi, and synthetic Pam3CSK4, and lipoteichoic acid (LTA) from
S. aureus, are shown. Residue numbers are written above the sequence.
The bold Rs in LTA represent substituting groups.
(B) The ligand-binding sites of the TLR1-TLR2 complex are shown in gray and
green, respectively. The molecular surface of the residues directly involved in
pocket formation is represented in mesh. Pam3CSK4 is drawn in red as
a space-filling model.
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because LRRs are very rigid structural frameworks, and struc-
tural transitions of this magnitude have not been reported. The
heterodimeric complex of TLR1 and TLR2 is further stabilized
by extensive protein-protein interactions near the ligand-binding
pocket. Interestingly, the Pro315Leu substitution in a polymor-
phic variant of TLR1 is located in the protein-protein interaction
interface (Omueti et al., 2007). This change blocks TLR1 signal-
ing in response to pathogenic lipoproteins, confirming that the
heterodimeric interaction shown in the crystal is essential for
lipoprotein signaling.
The crystal structure of the TLR1-TLR2-lipopeptide complex
provides a reasonable template for structure prediction of the
TLR1-TLR2-lipoteichoic acid (LTA) complex. LTAs are potent in-
ducers of innate immune responses via the TLR2-dependent
pathway (Deininger et al., 2003; Han et al., 2003; Schroder
et al., 2003). The LTAs of S. aureus are composed of two lipid
chains attached to glycerophosphate units repeated typically
from 4 to 25 times (Figure 1A andMorath et al., 2001). In solution,
LTA can induce the formation of a stable heterodimeric complex
between the purified extracellular domains of TLR1 and TLR2
(unpublished data). Because the two thioester-linked lipid chains
of the synthetic lipopeptides, Pam2CSK4 and Pam3CSK4, are
inserted into the TLR2 pocket in practically the same conforma-
tion, it is highly probable that the two lipid chains of LTAs are in-
serted into the binding pocket in TLR2 in a similar fashion. Be-
cause LTA has only two lipid chains, the hydrophilic sugars
and repeating units must also interact with TLR1 in order to
stabilize the TLR1-TLR2 complex in the absence of stabilization
of the TLR dimer by a third lipid chain.
TLR3-Ligand Interaction
TLR3 has been shown to recognize dsRNA produced during viral
replication (Alexopoulou et al., 2001). The crystal structure of
TLR3 bound to a dsRNA ligand has been reported (Figure 2
and Liu et al., 2008). The dsRNA interacts with both N-terminal
and C-terminal sites on the lateral side of the convex surface
of TLR3. The N-terminal interaction site is composed of LRRNT
and LRR1-3 modules, and the C-terminal site is composed of
LRR19-21 modules. The positively charged residues of the ter-
mini of TLR3 make the major contributions to the interaction
with the sugar-phosphate backbones of the dsRNA ligand.
Only a minor TLR3-TLR3 interaction is located near the LRRCT,
demonstrating that the ligand-protein interaction is the main
driving force for TLR3 dimerization. The ligand interaction sites
of the TLR3 homodimer are separated by 120 A˚, which ac-
counts for why aminimumof 40–50 base pairs is required for sta-
ble binding of dsRNA to TLR3 (Leonard et al., 2008). However,
there have been reports that dsRNA of substantially less than
40 bp can initiate TLR3 signaling (Kariko et al., 2004; Kleinman
et al., 2008). These reports raise the possibility that the N-termi-
nal interaction site may not be essential for efficient TLR3 signal
initiation in some experimental conditions. The interactions be-
tween TLR3 and dsRNA are very different from those between
TLR1-TLR2 and lipopeptides. Hydrophobic interactions make
the main contribution to ligand binding by the TLR1-TLR2 com-
plex (Jin et al., 2007). In contrast, the dsRNA interaction sites in
TLR3 are located on the surface of the protein, and ionic andhydrogen bonds with the sugar-phosphate backbones of the
ligand play the major role (Figure 2).
TLR4-Ligand Interaction
TLR4 in company with its coreceptor MD-2 is specific for LPS
recognition (Shimazu et al., 1999; Viriyakosol et al., 2001). Lipo-
polysaccharides (LPSs) are outer-membrane glycolipids of
Gram-negative bacteria and are well-known inducers of the in-
nate immune response (Erridge et al., 2002). They are composed
of a hydrophobic lipid A component and a hydrophilic polysac-
charide component. The lipid A portion is composed of phos-
phorylated diglucosamine and four to seven acyl chains
(Figure 3A). Chemically synthesized lipid A has the same biolog-
ical activity as full-sized LPS, demonstrating that it possesses
the same configuration (pattern) as LPS and is the main inducer
of biological responses to LPS (Tanamoto et al., 1984). Both the
1 and 40 positions of the glucosamine backbone of lipid A are
frequently phosphorylated. Phosphorylation is important for
the biological activity of LPS because diphosphorylated lipid A
is more than 1000-fold more active than monophosphorylated
lipid A (MPL) (Rietschel et al., 1987). The phosphate group can
Figure 2. TLR3-Ligand Interaction
Structures of the N-terminal (A) and C-terminal binding sites (B) of TLR3 are
shown. Ca traces of the LRR modules directly interacting with RNA are drawn
in pink. Residues of the RNA are numbered. The second TLR3 molecule in the
TLR3 homodimer is marked with a double apostrophe.
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mostly saturated lipid chains are linked to the sugar backbone
of lipid A through either ester or amide linkages. The lipid A moi-
ety is connected to the core oligosaccharide part of LPS. The
core sugar chain contains unusual Kdo (3-deoxy-D-manno-
oct-2-ulosonic acid) and heptose saccharides not normally
found in humans and is connected to the highly variable O-spe-
cific chain composed of repeating oligosaccharide units (Erridge
et al., 2002). The O-specific sugar chains are highly variable in
structure compared to the core sugar. The number of repeating
units can be anywhere from 1–50 in the same bacterium. The
sugar composition, sequence, chemical linkage, substitution,
and ring form of the repeating units can vary dramatically,
thereby making LPS of almost unlimited diversity. Experiments
using synthetic variants of lipid A demonstrate that E.coli lipid
A containing six lipid chains and two phosphate groups has
a nearly optimal structure for endotoxicity (Erridge et al., 2002;
Rietschel et al., 1991). Lipid A with five or seven acyl chains
Figure 3. TLR4-MD-2-Ligand Interaction
(A) Chemical structures of lipid A of E. coli, the syn-
thetic antagonist, Eritoran, and lipid IVa. Numbers
of carbons in the lipid chains are written below.
(B) Overall structure of the TLR4-MD-2 complex.
The left shows the top view, and the right shows
the side view.
(C) Structures of MD-2 complexed with the antag-
onistic ligands, Eritoran (left) and lipid IVa (right).
MD-2, Eritoran, and lipid IVa are colored orange,
black, and gray, respectively. Disulfide bridges
are represented as yellow lines. The molecular
surfaces of residues involved in formation of the
hydrophobic pocket of MD-2 are drawn in mesh.
is 100-fold less active, and structural
changes in the sugar or lipid chains in-
variably lead to substantially reduced
activity.
Several synthetic derivatives of lipid A
have been developed as candidate drugs
against sepsis and septic shock syn-
drome. Eritoran (or E5564) is a synthetic
molecule derived from the lipid A compo-
nent of the nonpathogenic LPS of Rhodo-
bacter sphaeroides (Figure 3A and Mul-
larkey et al., 2003). It is a strong
antagonist of TLR4-MD-2 and is currently
in a phase III clinical trial against severe
sepsis. The diglucosamine backbone
and the phosphate positions of LPS are
conserved in Eritoran. However, the num-
ber and chemical structure of the lipid
chains have noticeable differences that
make it an antagonist. For example, Eri-
toran has only four lipid chains and one
of them contains a double bond in cis
configuration. Lipid IVa, also called com-
pound 406, is an intermediate in LPS bio-
synthesis (Figure 3A and Kusumoto et al.,
2003). Interestingly, it is an antagonist of
human TLR4-MD-2 but a mild agonist of
the mouse form (Means et al., 2000; Tanamoto and Azumi,
2000). Both Eritoran and lipid IVa bound toMD-2 have been crys-
tallized, providing the first glimpse of the structural flexibility of
the ligands recognizing the TLR4-MD-2 complex (Kim et al.,
2007b; Ohto et al., 2007).
MD-2 adopts a b cup fold with two antiparallel b sheets that are
separated on one side, and with internal hydrophobic residues
exposed for ligandbinding (Kimet al., 2007b). The internal pocket
of MD-2 is completely lined with hydrophobic residues, but the
open region has positively charged residues. Therefore, the over-
all shape and electrostatic characteristics of MD-2 seem to be
suitable for binding negatively charged amphipathic ligands
such as LPS. Interaction between TLR4 and MD-2 is mediated
mainly by ionic and hydrogen bonds in two oppositely charged
patches. The negatively charged A patch of TLR4 interacts with
basic residues inMD-2.On the other hand, the positively charged
B patch that is located in a less conserved area of TLR4 interacts
with negatively charged residues in MD-2 (Figure 3B).
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tallized (Kim et al., 2007b). As with TLR1 and TLR2, the ‘‘hybrid
LRR technique’’ made a crucial contribution to crystallization
of the TLR4 complexes (discussed above). In the crystal struc-
ture, Eritoran binds to the hydrophobic pocket in MD-2, with its
four acyl chains occupying almost all the available space in the
pocket. There is no direct interaction between Eritoran and
TLR4. Because Eritoran mimics the structure of LPS and the
two compete for MD-2, these data suggest that MD-2 is the
only LPS-binding component of the TLR4-MD-2 complex (Visin-
tin et al., 2005). Another complex of human MD-2, this time with
bound lipid IVa, has been recently reported by Ohto et al. (2007).
Their structure contains no TLR4 subunit, and comparison of
their MD-2 structure with our TLR4-bound MD-2 structure indi-
cates that TLR4 binding causes only minor changes in the loops
of MD-2. The comparison also reveals that the mode of binding
of lipid IVa is remarkably similar to that of Eritoran despite the
structural differences between their lipid chains (Figure 3C).
The four lipid chains and phosphate groups occupy identical
sites in MD-2 and the glucosamine backbone is only shifted by
two angstroms.
As noted, both Eritoran and lipid IVa have tetra-acylated lipid
chains, whereas agonistic LPS has more or longer lipid chains
(Figure 3A). Because the lipid chains of Eritoran and lipid IVa oc-
cupy almost all the available space in the MD-2 pocket, LPS
must bind to MD-2 in a different fashion from Eritoran and lipid
IVa. Several structural adjustments of MD-2 can be envisaged.
In the first model, LPS may be able to enlarge the MD-2 pocket.
Because one edge of the b sandwich ofMD-2 is pulled away, and
no intersheet disulfide bridge is present, it appears to be possi-
ble to enlarge the pocket without excessive structural changes.
In the second model, structural changes of MD-2 are minimized,
whereas four of the chains of LPS are inserted into the MD-2
pocket with the remaining two chains protruding from the pocket
and able to interact with a second TLR4 molecule to promote di-
merization. Both of these modes of binding LPS should provoke
some structural changes in MD-2, and these may play an impor-
tant role in dimerization of the TLR4-MD-2 complex. Because the
phosphate groups of lipid A are known to be crucial for the high
potency of E.coli LPS, they may also have a direct role in dimer
formation.
Several lines of evidence support the hypothesis that ligand
binding induces aggregation of the TLR4-MD-2 complex and
that this initiates signaling. Miyake and colleagues discovered
that residues Phe126 and Gly129 of MD-2 are crucial for aggre-
gation of the TLR4-MD-2 complex (Kobayashi et al., 2006). In ad-
dition, we have conducted mutation and deletion experiments to
help build a reliable model of TLR4 dimerization and activation
(Kim et al., 2007b). We showed that binding of agonistic LPS
to purified TLR4-MD-2 complexes induces dimerization of the
complexes. Truncation of the C terminus of TLR4 prevented di-
merization. We also demonstrated using purified proteins that
Phe126 and His155, located on the same side of MD-2, are es-
sential for dimerization. These results can be explained by
a model in which LPS induces dimerization of TLR4-MD-2 by
altering the conformation of the Phe126 surface of MD-2 and ex-
posing otherwise hidden interaction sites for binding to the C-
terminal domain of the second TLR4 molecule. Interestingly, in
this model, the two TLR4 molecules form an ‘‘m’’-shaped com-plex similar to that of the TLR1-TLR2 heterodimer and TLR3
homodimer (Kim et al., 2007b). Recent biochemical data with
horse TLR4 and MD-2 supports our model (Walsh et al., 2008).
Many previous reports demonstrate that, in addition to MD-2,
TLR4 needs two accessory proteins, LBP and CD14, to recog-
nize LPS at physiological concentrations (Fujihara et al., 2003;
Miyake, 2003; Schumann et al., 1990). LBP is required for ex-
tracting LPS from the outer membrane of Gram-negative bacte-
ria or vesicles liberated by them, and for transferring it to CD14 in
a monomeric form. Because CD14 has no intracellular signaling
domain, LPS must ultimately be delivered to the TLR4-MD-2
complex to initiate immune responses. LBP belongs to the lipid
transfer or lipopolysaccharide binding protein (LT-LBP) family
(Mulero et al., 2002). Other current members of the family are
bactericidal and permeability-increasing protein (BPI), choles-
terol ester transfer protein (CETP), phospholipid transfer protein
(PLTP), and a few poorly characterized proteins. LBP andBPI are
especially similar in sequence (45% sequence identity) and func-
tion. They both bind to LPS and control its biological effects. BPI
is a plasma protein that neutralizes LPS. It is a boomerang-
shaped molecule composed of a central b sheet and barrel-
shaped domains at its termini (Beamer et al., 1997; Beamer
et al., 1999). Each barrel contains a long a helix surrounded by
a five-stranded antiparallel b sheet and a short a helix. It also
contains a hydrophobic pocket that binds a phospholipid mole-
cule, mainly by interacting with its acyl chains. The head group of
the phospholipid lies at the entrance of the pocket and is ex-
posed to solvent. Although the structure of LBP bound to LPS
has not been reported, the structure of BPI allowed homology
modeling of LBP (Beamer et al., 1998); the two proteins are
highly homologous and can be aligned with only two single
residue gaps. Therefore, LBP is predicted to have the same
boomerang-like two-barrel structure with two hydrophobic
phospholipid pockets. Mutational and domain-swapping
experiments have suggested that the N-terminal domain of
LBP is responsible for interaction with LPS and the C-terminal
domain mediates the transfer of LPS to CD14 (Abrahamson
et al., 1997; Iovine et al., 2002; Theofan et al., 1994). Although
the two barrels have an almost identical structural architecture,
their electrostatic characteristics appear to differ markedly.
Whereas the surface of the N-terminal barrel of LBP is strongly
positively charged, the C-terminal barrel does not seem to
have any particular overall charge. The expected charge distri-
bution may play a role in the transfer of LPS to CD14 because
BPI with its uniformly positive charge can bind LPS but cannot
transfer it to CD14.
CD14, which is found in soluble form or as a GPI-anchored
protein on the cell membrane, is another essential accessory
protein for LPS recognition (Ulevitch and Tobias, 1995). Our
crystallographic analysis shows that it is an LRR family protein
with 11 LRR modules (Kim et al., 2005). Unlike other LRR family
members, CD14 does not contain an LRRCT module protecting
its hydrophobic core. Instead, the C terminus of the LRR mod-
ules of CD14 interacts with the C terminus of another CD14 form-
ing a dimer. Therefore, their hydrophobic cores are covered by
the opposing monomers in the CD14 dimer. Interestingly, be-
cause dimeric CD14 contains 22 LRRmodules in total, its overall
shape and size appear to be comparable to those of TLRs. The
LPS interaction site of CD14 is located at the boundary of the
Immunity 29, August 15, 2008 ª2008 Elsevier Inc. 187
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for the hypothesis that the domain boundaries are crucial for
pocket formation in LRR family proteins. As in the TLR1-TLR2
complex, the LPS-binding pocket of CD14 is located in the con-
vex region formed by opening a crevice composed of flexible
loops and helices. The pocket is covered with purely hydropho-
bic residues except for the rim of the pocket, which contains hy-
drophilic and flexible residues. Several laboratories have re-
ported interesting mutational analyses showing that a distinct
region near the LPS-binding pocket of CD14 is crucial for LPS
signaling but not for LPS binding (Juan et al., 1995; Kim et al.,
2005; Muroi et al., 2002; Stelter et al., 1999). The data suggest
that this LPS signaling area may make direct and transient con-
tact with TLR4-MD-2 to achieve efficient LPS transfer. Additional
structural and biochemical studies are required to identify the
CD14 contact area in TLR4-MD-2 and ultimately to build a reli-
able model of the mechanism of LPS transfer between CD14
and the TLR4-MD-2 complex.
Ligand-Induced Activation of TLR Family Proteins
TLR family receptors interact with an unusually diverse variety of
ligands, ranging from hydrophilic nucleic acids to hydrophobic
LPS or lipoproteins (Akira and Hemmi, 2003; Gay and Gangloff,
2007). They also vary greatly in size from small synthetic mole-
cules to macromolecules. Regardless of these differences, the
structures of the TLR1-TLR2-lipopeptide, TLR3-dsRNA com-
plexes and the model of the TLR4-MD-2-LPS complex all have
an ‘‘m’’-shaped dimeric architecture, suggesting that all the
other TLRs undergo similar dimerization upon binding agonists
(Figure 4 and Jin et al., 2007; Kim et al., 2007b; Liu et al., 2008).
This observation immediately suggests the hypothesis that
dimerization of the extracellular domains brings about di-
merization of the intracellular TIR domains and so initiates signal-
ing. It is known that, in a membrane environment, full-length
TLRs exist as homomultimers or heteromultimers even without
their ligands (Akira and Takeda, 2004; Latz et al., 2007; Ozinsky
et al., 2000; Triantafilou et al., 2006). However, these preligand
complexes cannot induce intracellular signaling, probably be-
cause their TIR domains have an inappropriate orientation or dis-
tance for signaling. Dimerization of the extracellular domains
may lead to proper orientation of the TIRs, recruitment of adaptor
proteins, and initiation of intracellular signaling. Sequence align-
ment shows that only a few residues are able to act as flexible
linkers between the extracellular and transmembrane domains
and between the transmembrane region and the intracellular do-
main (Bell et al., 2003). Therefore, close apposition of the C ter-
mini of the ectodomains is very likely to encourage juxtaposition
of the intracellular TIR domains, as shown in the model.
Conclusions
TLR family receptors have a common structural architecture.
The extracellular domains of TLRs belong to the well-known
LRR family with multiple LRR modules. Sequence and structure
analyses demonstrate that TLR1, TLR2, TLR4, TLR6, and TLR10
belong to the three-domain subfamily; they bind to and are acti-
vated by hydrophobic ligands such as lipoproteins, LTA, LPS,
etc. Conversely, TLR3, TLR5, TLR7, TLR8, and TLR9 belong to
the single-domain subfamily. These TLRs interact with hydro-
philic proteins or nucleic acids. The structures of the TLR1-
188 Immunity 29, August 15, 2008 ª2008 Elsevier Inc.TLR2 heterodimer and TLR3 homodimer induced by binding of
agonistic ligands have revealed a common ‘‘m’’-shaped archi-
tecture. In these dimeric arrangements, the C termini of the ex-
tracellular domains of TLRs converge in the center, and such
a convergence should bring the two intracellular TIR domains
close together and so promote their dimerization.
Additional structural studies of the TLR system are needed to
address several key issues in innate immune research: (1) TLRs
recognize ‘‘pattern’’ in structurally diverse ligands. Previous
studies have shown that even minor modifications to ligands
may lead to unpredictable changes in the immune responses
that they evoke. We need to define precisely the meaning of
‘‘pattern’’ in TLR ligands, not only to better understand the innate
immune system but also to be able to design improved antago-
nists and agonists for clinical use. For this purpose, structural
studies of TLRs complexed with diverse ligands are essential.
(2) Common structural principles of TLR dimerization and activa-
tion appear to emerge from structural studies of the TLR2 and
TLR3 complexes. It will be important to see whether other
Figure 4. Ligand-Induced TLR Dimers
The ‘‘m’’-shaped TLR dimers induced by binding of agonistic ligands. The
crystal structures of (A) TLR1-TLR2-Pam3CSK4 and (B) TLR3- dsRNA are col-
ored gray, green, red, pink, and purple, respectively. (C) shows a model of the
TLR4-MD-2-Eritoran complex. TLR4, MD-2, and Eritoran are colored light
blue, orange, and black, respectively. Double apostrophes are used to mark
the second TLR4 or MD-2 in the receptor complex.
Immunity
ReviewTLRs complexed with different ligands dimerize in a similar fash-
ion. (3) There are several models of TIR multimers. Therefore, ex-
perimental structure analysis of multimers composed of the TIR
domains of TLRs and adaptor proteins is crucial for improving
our understanding of the TLR signal pathway.
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